



## **TRACON to Report First Quarter Company Highlights and Financial Results on May 10, 2017**

**San Diego, CA – May 3, 2017** – TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that it will report its first quarter financial and operating results after the close of U.S. financial markets on Wednesday, May 10, 2017. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.

Conference call and webcast:

Date: May 10, 2017

Time: 4:30 pm Eastern Time (1:30 pm Pacific Time)

Dial-in: (855) 779-9066 (Domestic) or (631) 485-4859 (International)

Passcode: 15138572

Via web: [www.traconpharma.com](http://www.traconpharma.com); “Events and Presentation” section within the “Investors” section

A replay of the webcast will be available for 60 days on the website.

### **About TRACON**

TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule that is being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at [www.traconpharma.com](http://www.traconpharma.com).

#### Company Contact:

Casey Logan  
Chief Business Officer  
(858) 550-0780 ext. 236  
[clogan@traconpharma.com](mailto:clogan@traconpharma.com)

#### Investor Contact:

Andrew McDonald  
LifeSci Advisors LLC  
646-597-6987  
[Andrew@lifesciadvisors.com](mailto:Andrew@lifesciadvisors.com)